X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-suvorexant-calquence-tablets-79647.pdf
https://www.neurologylive.com/view/suvorexant-increases-sleep-time-in-patients-with-alzheimer-dementia-insomnia
http://www.pmlive.com/pharma_news/merck_gets_alzheimers_label_claim_for_insomnia_drug_belsomra_1324234
https://www.clinicaltrialsarena.com/comment/daridorexant-insomnia-potential/
https://www.biospectrumasia.com/news/39/14759/world-first-clinical-trial-commences-in-alcohol-use-disorder.html
https://www.clinicaltrialsarena.com/news/alcohol-use-disorder-trial/
https://www.businesswire.com/news/home/20190507005113/en/Merck%E2%80%99s-BELSOMRA%C2%AE-suvorexant-C-IV-Meets-Primary-Efficacy/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J
http://www.fiercepharmamarketing.com/story/pharmas-dtc-ad-spending-soars-past-5-billion-2015/2016-03-07
http://www.fiercepharmamarketing.com/story/jardiance-belsomra-and-entyvio-brand-managers-share-dtc-honors-oldsters-via/2016-02-29
http://www.fiercepharmamarketing.com/story/abbvies-humira-repeats-joined-bms-opdivo-leading-tv-spending-october/2015-11-18
http://www.fiercepharmamarketing.com/story/real-life-insomnia-stories-core-new-merck-backed-awareness-campaign/2015-11-09
http://www.forbes.com/sites/arleneweintraub/2015/06/04/mercks-quest-to-revive-the-market-for-insomnia-drugs/?ss=pharma-healthcare
http://www.fiercepharmamarketing.com/story/merck-execs-tout-early-yield-sleep-drug-belsomras-launch/2015-03-11
http://www.mercknewsroom.com/news-release/prescription-medicine-news/mercks-insomnia-medicine-belsomra-suvorexant-c-iv-first-and-
http://www.pharmatimes.com/Article/15-02-03/US_roll_out_for_Merck_s_first-in-class_sleep_drug.aspx
Market Place
Share 
